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Summary points
• Our analysis of experience from programmes targeting malaria, leprosy and TB shows
the importance of drawing broadly on research and implementation expertise, and civil
society more broadly, when setting targets for HIV control. The engagement of stake-
holders from the highest burden settings, including affected populations, is crucial, to
ensure that disease control efforts uphold human rights and tackle HIV-related stigma
and discrimination.
• An appropriate balance is needed between ambitious, galvanising global targets that
drive funding and political/public engagement, and targets that reflect the complexities
and local epidemiological variations in disease profile. Ethical issues and unintended
consequences need to be considered when setting targets—particularly around local
effects and opportunity costs of having foregone other areas of disease control and pub-
lic health. Intermediate and adaptable targets are needed that allow for course correc-
tions to programmes.
• Overly burdensome reporting requirements for individual local programmes and coun-
tries should be avoided, as well as potential for overlapping and sometimes conflicting
targets both within and across vertical disease programmes. Process targets should be
distinguished from outcome targets, which should be measurable and based on high-
quality data.
• Retention of expert healthcare worker skills and specialist services is vital, while moving
towards integrated health systems if effective disease control programmes are to be main-
tained. Target development should seek areas of programme delivery where an opportu-
nity to codevelop targets and integrate services exists. Global efforts to move to universal
health coverage (UHC), for example, could be factored in when developing targets.
• Sustaining investment and continuing political interest in the end phase of any elimina-
tion or eradication strategy, once incidence and prevalence are low, are critical to
achieve success. Equity- and access-based service delivery targets become increasingly
important as the elimination strategy nears its end and should be factored into
planning.
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• Achieving disease elimination and/or eradication is only possible with sufficient invest-
ment in research to develop new prevention tools such as vaccines, point-of-care diag-
nostics, and treatments to counteract the effects of increasing drug resistance and the
challenging latency period of diseases; public health infrastructure upgrades that address
wider determinants of health; and health and surveillance systems that allow for equita-
ble delivery and access to services.
Introduction
Over the last four decades, efforts to address the global HIV pandemic have required multidis-
ciplinary and multisectoral approaches adapted to different contexts [1]. The complex epide-
miology of HIV and the breadth of scientific, societal, and political stakeholders involved in
the global response have posed challenges in terms of coordination, harmonisation, and fund-
ing. Concerted advocacy and successive global strategies to prevent and control HIV have had
a major influence on the global availability of political and financial support and on national
response strategies [2]. However, the campaign against HIV highlights both the importance of
globally agreed definitions and the challenges of developing a common understanding of over-
arching goals, targets, and measures of progress.
As future global targets for the control of HIV are considered [3], we aim in this article to
identify relevant lessons from control programmes for three other global infectious diseases—
malaria, leprosy, and tuberculosis (TB). These were chosen because they have been the subject
of international control efforts, with varying levels of success, and because they illustrate many
of the problems faced by HIV control. These three programmes have faced challenges in reach-
ing clear definitions of the concepts essential to epidemic control (Table 1), in sustaining polit-
ical will and resources, and in meeting the needs of hard-to-reach subgroups. In the following
sections, we briefly summarise epidemiological comparisons between these diseases and HIV
(see Table 2) and then analyse the evolution of each disease control programme from the
Table 1. Essential terms and concepts for defining goals and targets to limit infectious disease epidemics [4].
Control Nonspecific term for reduction of disease incidence, prevalence, morbidity, and/or
mortality to a locally acceptable level as a result of deliberate efforts; continued
intervention measures are required to maintain the reduction.
Elimination of transmission A reduction to zero of the transmission of infection caused by a specific pathogen
in a defined geographical area, with minimal risk of reintroduction, as a result of
deliberate efforts; continued actions to prevent re-establishment of transmission
may be required.
Verification The process of documenting elimination of transmission.
Elimination as a public health
problem
Defined by achievement of measurable global targets set in relation to a specific
disease. When reached, continued actions are required to maintain the targets
and/or to advance the interruption of transmission.
Validation The process of documenting elimination as a public health problem.
Eradication The permanent reduction to zero transmission of a specific pathogen as a result of
deliberate efforts, with no more risk of reintroduction.
Certification The process of documenting eradication.
Extinction Eradication of a specific pathogen so that it no longer exists in nature or the
laboratory.
https://doi.org/10.1371/journal.pmed.1002735.t001
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Table 2. Epidemiological comparison of the four diseases considered.
Features Malaria TB Leprosy HIV/AIDS
Transmission Caused by the Plasmodium parasite and
spread to people through the bites of
infected female Anopheles mosquitoes.
There are five parasite species
(including P. falciparum and P. vivax)
that cause malaria in humans [5].
There is no animal reservoir in nature.
Caused by a bacterium (Mycobacterium
tuberculosis) and most often affects the lungs.
Spread from persons with active infection
through droplets in the air. Approximately
one third of the world’s population has latent
TB (long-term asymptomatic infection), but
they have only a 10% lifetime risk of
becoming sick with TB. If not treated, each
person with active TB infects on average 10
to 15 people each year [6]. The proportion of
human cases of TB caused by M. bovis
(bovine TB) is estimated at <5% [7].
Caused by a bacterium (M. leprae).
Transmission is favoured by close
contact. May be transmitted from
nasal mucosa, possibly through
respiratory secretions, but the exact
mechanism is not clearly understood.
Over 85% of clinical cases are
noninfectious. Evidence suggests
infectiousness is lost in most instances
within a few days of beginning MDT
[8]. Zoonotic transmission of leprosy
from armadillos to humans has been
recorded in the Southern United
States and parts of South America [9].
Caused by the human immunodeficiency
virus; left untreated (2 to 15 years
postinfection), acquired
immunodeficiency syndrome (AIDS)
develops. HIV is transmitted person to
person by unprotected sexual
intercourse; use of HIV-contaminated
injecting and skin-piercing equipment;
vertically from mother to infant during
pregnancy, delivery, or breastfeeding; or
transfusion of infected blood or its
components [10].
Who is at
risk?
Those at highest risk of severe disease
are those with the lowest immunity:
infants and young children, pregnant
women and patients with HIV/AIDS,
nonimmune migrants, mobile
populations, and travellers. Seventy
percent of malaria deaths occur in
children under 5 years [5].
Active TB mostly affects adults in their
productive years. People who are infected
with HIV are 20 to 30 times more likely to
develop active TB. The risk of active TB is
also greater in persons suffering from
malnutrition or diabetes, and smokers [6].
Persons at highest risk live in endemic
areas in close contact with
multibacillary cases. Genetic factors
play a part in determining the risk of
disease [11]. Leprosy reactions may be
masked in patients with advanced
HIV disease. Children under 14, as
well as older adults, may be at
particular risk of leprosy infection
[12].
Heterosexual sexual transmission is the
predominant mode of HIV transmission
in the sub-Saharan Africa and South-East
Asia regions, with young women
particularly vulnerable. Many epidemics
are occurring among high-risk groups,
including sex workers and men who have
sex with men. Injecting drug use is a
major mode of transmission in Eastern
Europe and Central Asia. Without
preventive interventions, the likelihood
of transmission from infected mothers to
their children is 15%–45% [13].
Disease
burden
In 2017, ongoing malaria transmission
was present in 90 countries and areas.
There were an estimated 219 million
cases of malaria, 435,000 deaths, and the
incidence rate of malaria was estimated
at 63 cases per 1,000 population at risk.
A total of 92% of malaria cases are in
Africa and 93% of malaria deaths. P.
falciparum is the most prevalent malaria
parasite in sub-Saharan Africa,
accounting for 99% of estimated
malaria cases [5].
Over 95% of cases and deaths are in LMICs.
In 2016, 45% of new cases occurred in Asia,
and 25% in Africa. A total of 74% of people
coinfected with TB-HIV in 2016 live in
Africa [6].
Globally in 2016, there were an estimated 1.7
billion people infected with TB and an
estimated 10.4 million incident cases of TB
(range, 8.8 million to 12.2 million),
equivalent to 140 cases per 100,000
population [14].
In 2017, the estimated global
prevalence of leprosy was 0.25 per
10,000 population, and the rate of
detection of new cases was 2.77 per
100,000 population [15]. In 2015,
India reported 127,326 newly
diagnosed cases (60% of those
reported globally); Brazil reported
26,395 (13% of those reported
globally); and Indonesia reported
17,202 (8% of those reported globally)
[16]. The majority of countries with a
high number of newly diagnosed cases
are located in the Africa and South-
East Asia WHO regions.
Approximately 36.9 million people were
living with HIV at the end of 2017
globally, and 1.8 million people became
newly infected with HIV in 2017. Sub-
Saharan Africa is the most affected
region, with 25.7 million people living
with HIV in 2017. The WHO Africa
region accounts for over two thirds of the
global total of new HIV infections each
year. Current estimates suggest that 75%
of people living with HIV know their
status [17].
Prevention Vector control by use of insecticide-
treated mosquito nets and indoor
residual spraying.
Intermittent preventative treatment for
pregnant women and infants in areas of
moderate to high malaria transmission
in Africa.
Seasonal malaria chemoprevention in
children under the age of 5 years in
areas of high seasonal transmission in
the Sahel, Africa [5].
Early diagnosis and treatment to stop
transmission, chemoprophylaxis for latent
TB in young children and those coinfected
with HIV or immunocompromised, and
BCG vaccine [14].
Early detection and prompt MDT of
cases, and evaluation and treatment of
infected household contacts. Early
detection and treatment with MDT
has prevented about 4 million people
from becoming disabled [8].
Safer sexual behaviour, including male
and female condom use; testing and
counselling for HIV and STIs; medical
male circumcision; ARV drug use for
prevention (pre-exposure prophylaxis)
and treatment as prevention; harm
reduction for injecting drug users;
elimination of mother-to-child
transmission [18].
Diagnosis Parasite-based diagnostic testing—can
either be by microscopy or rapid
diagnostic test—for which results can be
available within 30 minutes [5].
Most countries still rely on sputum smear
microscopy; however, microscopy detects
only half the number of TB cases and cannot
detect drug resistance. Since 2010, the rapid
test Xpert MTB/RIF has become more
available. Diagnosis can be made within 2
hours, requires less technical expertise, and
can detect resistant strains [6].
Clinical diagnosis is based on
complete skin examination, involving
identification of skin lesions,
peripheral nerve involvement, or
motor weakness and sensory loss.
Laboratory diagnosis is through
identification of acid-fast bacilli in slit
skin smears or by full thickness skin
biopsy. In practice, laboratory studies
are not essential for the diagnosis of
leprosy, although confirmation by
skin biopsy is recommended [19].
Serological tests (e.g., rapid diagnostic
tests or enzyme immunoassays) can
detect the presence or absence of
antibodies to HIV-1/2 and/or the HIV
p24 antigen [20]. HIV self-testing does
not provide a definitive diagnosis but is
an initial test that requires further testing
by a health worker using a nationally
validated testing algorithm [21].
(Continued)
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1950s onwards, focusing on the stated global control strategy, specific targets, and major global
events or initiatives (see S1 Table and Figs 1–4). Finally, we discuss how experience from these
programmes may inform the setting of future goals and targets for HIV.
Malaria
In 1955, the World Health Assembly (WHA) adopted a Global Malaria Eradication Cam-
paign (GMEP) involving indoor spraying with dichlorodiphenyltrichloroethane (DDT) and
Table 2. (Continued)
Features Malaria TB Leprosy HIV/AIDS
Treatment Malaria is curable. For P. falciparum,
malaria ACT is recommended [5].
However, counterfeit antimalarials are
an increasing global problem [22].
The great majority of TB cases can be cured
by four antimicrobial drugs taken properly
over 6 months. However, MDR TB and
extensively drug-resistant TB do not respond
as well to second-line treatments and can
require 2 or more years of treatment. In
2016, 35 Asian and African countries saw the
introduction of new second-line drugs that
have shortened the length of MDR TB
regimens [6].
MDT—combined chemotherapy with
rifampicin, dapsone, and clofazimine
—is available free of charge to most
countries from WHO or through
national health programmes. The
number of skin lesions is used to
guide treatment. The standard WHO
regimens are (a) a 12-month oral
course of MDT for adults with more
than five skin lesions and (b) a
6-month oral course of rifampicin and
dapsone for adults with two to five
skin lesions [23].
Combination ART consisting of three or
more ARV drugs can control the virus by
lowering viral load and helping prevent
onward transmission. New WHO
guidelines in 2016 recommended
provision of lifelong ART to all children,
adolescents, and adults, including all
pregnant and breastfeeding women living
with HIV, regardless of CD4 cell count
[24].
Resistance Vector control is dependent on the use
of pyrethroids, the only class of
insecticides recommended for ITNs or
LLINs. Mosquito resistance to
pyrethroids has emerged, but there is
believed to be no decreased efficacy of
LLINs. Rotational use of different
classes of insecticides for indoor
spraying is one approach to managing
resistance [5].
Resistance to antimalarial medicines is
also a recurring problem, with
chloroquine and sulfadoxine-
pyrimethamine (SP) developing
resistance in the 1950s and 1960s.
Recently, parasite resistance to
artemisinin has been detected in five
countries of the Greater Mekong
subregion [5].
Resistant TB strains have developed through
the use of incorrect prescriptions, poor
quality drugs, and patients stopping
treatment prematurely.
MDR TB is resistance to two of the most
powerful first-line drugs, rifampicin and
isoniazid. In 2016, there were 490,000 people
with MDR TB, approximately half of whom
lived in China, India, or the Russian
Federation, but only 54% were successfully
treated. In 2016, about 6.2% of MDR TB
cases had XDR TB, which means resistant to
second-line drugs, and only 30% were
successfully treated [6].
In the 1960s, M. leprae started to
develop resistance to dapsone, the
world’s only known anti-leprosy drug
at that time. Today, there are ‘a few
isolated reports of rifampicin-resistant
leprosy, mainly from areas where
rifampicin was given as monotherapy,
either alone or in combination with
dapsone, to dapsone-resistant
patients’ [25]. Resistance to
rifamipicin, the most important
component of MDT, appears to be
associated with noncompliance with
dapsone or clofazimine regimens.
HIV drug resistance rapidly appears if
only one or two ARV drugs are used, if
treatment adherence is poor, or if there
are interruptions in treatment. The
rollout of ART has been accompanied by
increases in resistance at the population
level; research has shown that in the first
10 years (2001–2011) of mass treatment
rollout, non-nucleoside reverse
transcriptase inhibitors resistance
increased by 36% per year in East Africa
and by 23% in Southern Africa [26]. A
recent WHO report found that urgent
attention is needed to decrease levels of
loss to follow-up, support retention,
maximise adherence, and prevent drug
stock outs [27].
Vaccine
development
More than 30 P. falciparum malaria
vaccine candidates are at advanced
preclinical or clinical stages of
evaluation, but only the RTS,S/AS01
vaccine has completed Phase 3 trials
and passed a positive regulatory
assessment. In November 2016, WHO
announced that the RTS,S vaccine
would be rolled out in pilot projects in
three countries in sub-Saharan Africa
[5]. Potential shortcomings of the
vaccine are that it is partially effective
and requires three primary doses
followed by a booster [28]. Of the trial
participants given a four-dose schedule
starting at 5–17 months of age, vaccine
efficacy against severe malaria was
31.5% (95% CI 9.3–48.3) over about 4
years of follow-up [29].
BCG vaccine does prevent infection and is
partially effective in preventing miliary TB in
young children. A new vaccine that can
prevent infection is key to addressing the
reservoir of infection required to achieve the
End TB strategy. There are 16 different TB
vaccine candidates, but none have passed
Phase II trials yet [30].
BCG vaccine has a protective effect
against leprosy. One meta-analysis
suggested an overall protective effect
of 26% based on seven experimental
studies [31]. Trials are underway in
India to investigate protection
provided by a vaccine based on M.
indicus pranii [32].
HIV vaccine development is complicated
by the extreme variability of the virus
and, in particular, its envelope protein at
both the individual and population level.
A large multiyear clinical trial (HVTN
702) of a new vaccine is currently
underway in South Africa [33].
Abbreviations: ACT, artemisinin-based combination therapy; ART, antiretroviral therapy; ARV, antiretroviral; BCG, bacille Calmette-Gue´rin vaccine; HVTN, HIV Vaccine
Trials Network; ITN, insecticide-treated bednet; LLIN, long-lasting insecticide-treated bednet; LMIC, low- or middle-income country; MDR TB, multidrug-resistant TB;
MDT, multidrug therapy; SP, sulphadoxine-pyrimethamine; STI, sexually transmitted infection; TB, tuberculosis; XDR TB, extensively drug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002735.t002
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treatment of malaria [34]. Eradication was defined as the ‘global extinction’ of the parasite
[35].
The GMEP succeeded in eliminating malaria from many parts of the world [34], but in
sub-Saharan Africa, where mortality is highest, eradication was deemed technically unfeasible
and was finally abandoned in 1969. In retrospect, it was clear that the humanitarian appeal of
the campaign and subsequent urgency had led to an oversimplification and standardisation of
the programme. In the ‘consolidation phase’, the improvements in malaria control could not
be maintained without well-developed public health infrastructure. The continued high expen-
diture in an environment of greatly reduced transmission and disease incidence was difficult
to defend. And finally, increasing resistance both of vectors to DDT and the parasites to chlo-
roquine sealed the GMEP’s fate [34]. These lessons are relevant to attempts to end any disease,
including HIV/AIDS.
The following two decades saw a resurgence of the disease due to de-skilled and under-
resourced programmes, compounded by political instability from multiple conflicts and post-
colonial turmoil. The Roll Back Malaria (RBM) initiative of the 1990s was the first sign of
renewed international interest [36].
In October 2007, the Bill & Melinda Gates Foundation, endorsed by WHO, announced a
renewed ambition to eradicate malaria. However, most technical experts agree that malaria
elimination and subsequent eradication cannot be achieved with existing tools but will require
the development of new tools and approaches [37,38].
Malaria elimination, defined as a state in which interventions have interrupted endemic
transmission within a geographic area with minimal risk of re-establishment [35], may be
realistic for Asia, southern America, and parts of Africa. South Africa is aiming to eliminate
malaria before 2020 [39]. Elimination is a particularly attractive target for combating drug
resistance in Southeast Asia. But will this process be time limited or will sustained suppres-
sion through control efforts be required indefinitely [35]? Socioeconomic and environmen-
tal development in Europe and North America allowed for the relaxation of control
measures there. The development of a highly effective vaccine that can interrupt transmis-
sion and decrease the risk of transmission from mosquitoes, or gene editing of female
Fig 1. Major goals and targets for malaria. MDG, Millennium Development Goal; WHA, World Health Assembly.
https://doi.org/10.1371/journal.pmed.1002735.g001
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mosquitoes so that they can carry only male-producing eggs may be important parts of a
solution [40].
As a result of scaling up malaria control efforts, between 2000 and 2015, the world saw an
estimated 37% reduction in incidence and a 60% decline in mortality rates [41], thus realising
Millennium Development Goal (MDG) 6. However, the WHA target to reduce the global bur-
den of malaria by 75% by 2015 [42] and the RBM target to reduce deaths to near zero by the
end of 2015 have not been attained [43]. In 2017, there were 219 million cases of malaria glob-
ally, 92% of them in Africa, of which 99% were Plasmodium falciparum where the incidence
rate in 2016 was 206 cases per 1,000 population at risk [5].
The recent Global Technical Strategy for malaria 2016–2030 [44] advocates a combination
of control measures for highly endemic regions (reducing mortality by 90% and incidence by
90% compared with 2015), investment in malaria elimination in 35 countries with low malaria
incidence [45], preventing re-establishment in malaria free countries, and research into devel-
oping novel interventions. Given the shortfall in financial resources (in 2017, US$3.1 billion
were invested, half the minimum US$6.5 billion estimated to be required) [5], investment in
shrinking the malaria map should not be at the expense of funding for countries with the high-
est burden of disease.
Leprosy
Both leprosy and HIV/AIDS are chronic rather than acute infectious diseases, requiring long-
term management and treatment, and disproportionately affecting marginalised groups. How-
ever, leprosy differs from HIV in that multidrug therapy (MDT) cures leprosy infection and
can be discontinued, while HIV requires lifelong treatment to suppress, not cure, infection.
A surge in funding for MDT rollout, shortened treatment regimens, and changing case defi-
nitions of leprosy led to a considerable decrease in recorded leprosy prevalence by the end of
the 1980s [46]. Amid global progress and optimism, the WHA passed a resolution in 1991
seeking to ‘eliminate leprosy as a public health problem by 2000’, defining elimination as
reduction of prevalence to less than 1 in 10,000 globally. The 1/10,000 target was chosen arbi-
trarily, with limited consultation [47]; it was thought that attaining this prevalence would
Fig 2. Major goals and targets for leprosy.
https://doi.org/10.1371/journal.pmed.1002735.g002
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eventually interrupt leprosy transmission, but it was not supported by evidence (e.g., from
modelling) [48].
At the global level, the prevalence target of 1/10,000 was achieved by the end of 2000, with
all but six countries reaching the target nationally by 2005. (Success in achieving the target was
contingent on the use of the whole world population—including populations with very few
leprosy cases, e.g., in Northern Europe—as the denominator.) However, particularly in coun-
tries with a significant disease burden such as India and Brazil, continuing high numbers of
new cases detected indicated that MDT had not interrupted transmission as anticipated [49].
Since 2005, declines in both prevalence and incidence rates have largely stalled [50], and many
countries with a national prevalence below 1/10,000 continue to have high incidence subna-
tionally [51]. Arguably, attaining the global target has represented an advance in leprosy con-
trol rather than elimination [52]. In 2017, the estimated global prevalence of leprosy was 0.25
per 10,000 population, and the rate of detection of new cases was 2.77 per 100,000 population
[15].
Leprosy elimination efforts have been complicated by the disease’s long latent period (of up
to 20 years), the lack of a single diagnostic tool enabling early detection, and the complex and
varied clinical presentation. From an operational perspective, recent declines in case detection
and case identification activities in high-endemic settings have negatively affected diagnosis
and treatment coverage [53]. Indeed, there is evidence that pressure to achieve the elimination
target at the national level may have led to less active case finding, diagnosis, and reporting,
thus artificially resulting in lower prevalence figures [54].
A 2003 independent evaluation of the Global Alliance for the Elimination of Leprosy rec-
ommended a leprosy control approach focused on rehabilitation and preventing nerve dam-
age, rather than elimination [55]. WHO officially abandoned the elimination target of 1/
10,000 in 2007, and newer targets in WHO’s five-yearly plans have shifted towards prevention
of secondary disability, with targets for the reduction of grade 2 disabilities (G2D, defined as
visible deformity or damage present in the hands and feet, or severe visual impairment). How-
ever, despite the 2011–2015 WHO plan’s target of reducing the rate of G2D by 35% [56], there
was no decrease in G2D between 2010 and 2013 [50].
The 2016–2020 strategy includes targets around reducing G2D and discrimination, under-
pinned by 23 performance indicators, six guiding principles, and three pillars [57]. It is
instructive for HIV control to compare the complexity of the current leprosy control targets
with the simple elimination target chosen in 1991. The advocacy and resources behind the 1/
10,000 prevalence target put leprosy firmly on the global health agenda and helped detect and
cure many cases. The no-cost delivery of MDT to endemic countries meant that, at the global
level, the elimination programme was highly equitable (although some individuals had poor
outcomes) [58]. However, the perception that elimination was imminent, even as transmission
continued, resulted in reduced funding for leprosy programmes in the 2000s and the loss of
specialist leprosy services, as diagnosis and management of leprosy became integrated into
peripheral health services [59]. The elimination target also became politically charged, leading
to tensions between civil society organisations and global or national leprosy programmes
[55]. Furthermore, elimination rhetoric may have reduced scientific interest in leprosy, despite
significant evidence gaps [50]. For example, the International Journal of Leprosy ceased publi-
cation in 2005 [60], while research and development on vaccines has largely stalled (although a
new clinical trial of a candidate vaccine was launched in India in 2017) [61].
In terms of implications for HIV control, the example of leprosy highlights both the bene-
fits and hazards of setting strong, high-level targets. While there was significant progress in
expanding access to treatment, the initiative did not recognise the complexity of leprosy elimi-
nation and did not take into account the importance of long-term disability of individuals
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who had ceased to be counted as cases. Leprosy demonstrates the misalignment between
achieving a high-level target and implementation, in which efforts often did more to control
than to end leprosy.
TB
Following the Second World War, industrialised countries witnessed rapid declines in TB
incidence of approximately 10% per year [62] associated with socioeconomic development,
including reductions in overcrowding and improved living conditions, nutrition, and hygiene
[63]. Effective TB control was further aided by the advent of chemotherapy, universal access to
healthcare in many countries, and TB-specific vertical programmes.
By the early 1960s it had become clear that a vertical programme approach was too costly
for low-income countries. From the mid-1960s there was a move to integrate TB service deliv-
ery into general health services, with the hope of increasing coverage and reducing costs [63].
The early 1990s witnessed a sharp rise in TB notifications linked to the advent of the HIV
epidemic and dissolution of the former Union of Soviet Socialist Republics’ (USSR) structures.
In 1993, WHO declared a ‘global TB emergency’ [64], and targets were set for the turn of the
millennium that aimed at reducing TB incidence by 5%–10% annually [65]. A new Directly
Observed Treatment, Short Course (DOTS) strategy was launched, focussing primarily on
increasing cure rates and improving case detection. A vertical DOTS-based strategy was widely
promoted, with specialist managerial functions implemented at central, regional, and district
levels and delivery carried out through primary healthcare infrastructure [66]. Although drug-
resistant TB was recognised at this point, the DOTS strategy assumed that increasing adher-
ence and cure rates would prevent the spread of multidrug-resistant TB (MDR TB), and access
to MDR TB treatment was limited.
The targets for 2000 were met in 2005 due to improvements in living conditions and DOTS
in China, India, and Indonesia, the countries with the highest burden of disease then and now
[14], but many countries did not meet them. The Global Plan to Stop TB, 2006–2015 set bold
Fig 3. Major goals and targets for TB. DOTS, Directly Observed Treatment, Short Course; MDG, Millennium Development Goal; TB,
tuberculosis.
https://doi.org/10.1371/journal.pmed.1002735.g003
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new targets to halve the prevalence and death rates of TB by 2015 (as compared with the esti-
mated prevalence in 1990).
By 2015, with active TB incidence falling by an average of 1.5% per year since 2000, the
MDG to ‘halt and reverse TB incidence’ was met globally [67]. Globally, TB mortality has fallen
by 47% between 1990 and 2015, and the prevalence was almost half that of the 1990 estimate
[67]. However, there is considerable variation in outcomes between countries, and with the
growth of populations, the absolute number of new TB infections globally has grown, hence
the current approach to target high-burden countries, similar to the US President’s Emergency
Plan for AIDS Relief (PEPFAR) approach to HIV [68].
In 2014, the WHA approved the WHO End TB strategy, 2016–2035, which sought to
reduce annual incidence of active TB to less than 10 cases per 100,000 population by 2035.
This would mean that, of the 8.5 billion people expected to be alive in 2035, the number of new
cases of active TB would need to be fewer than 900,000 [69], as compared with the estimated
10.4 million new TB cases in 2016, equivalent to 140 cases per 100,000 population [14]. The
decline in active TB incidence has never been more than 1%–2% per year at the global level
[70]. To meet this target, the strategy ambitiously assumes that the incidence rate falls at 10%
annually between 2015 and 2025 through the optimisation of current tools and significant
progress in achieving the Sustainable Development Goals (SDGs), and then declines further at
an average of 17% annually with the advent of new technologies including a vaccine, new drug
treatments for active and latent disease, and point-of-care diagnostics [71]. Modelling studies
suggest that achieving the SDGs would have the most significant impact on the incidence of
active TB, but most of our efforts still focus on improving drugs and technologies [72]. Key
challenges include preventing, diagnosing, and treating MDR TB. In 2016, approximately 22%
of MDR TB patients were enrolled in second-line treatment, while treatment success is only
54% globally. But also important is the large, global reservoir of latent TB infection. Even if
transmission were completely interrupted from now onwards, reactivation and relapse would
still generate more than 10 active cases per 100,000 in 2050 [69]. Active TB incidence could be
brought down quickly with the discovery of a vaccine to prevent infection and a postinfection
vaccine that could neutralise the reservoir of latent infection [69].
Achieving global TB control requires high-incidence countries to have systems and strate-
gies to be able to accurately diagnose and deliver treatment early, universal healthcare cover-
age, and social protection to achieve high cure rates of active TB and MDR TB, coupled with
the necessary social and economic development to sustain achievements. In short, the End TB
Strategy elimination targets cannot be achieved without both rapid and substantial progress
towards the SDGs [73,74], and the development of a simple and effective mechanism for man-
aging latent infection.
HIV
Early in the HIV/AIDS epidemic, there were limited targets at the global level. These have
since developed into increasingly numerous, complex target frameworks. This section briefly
summarises different HIV targets at the global level, omitting the many specific national- and
community-level targets.
High-profile global HIV targets were first defined in the 2000 MDGs. The MDGs did not
specify quantitative targets, stating an aim to ‘halt and reverse’ the epidemic, without defining
this precisely [75]. The Declaration of Commitment on HIV/AIDS of 2001 set out more
detailed time-bound goals and targets [76], with an emphasis on transparency, accountability,
and ongoing reporting that owes much to concerted, determined civil society activism [77].
Progress against the 2001 Declaration’s targets was systematically reported in 2006 [78],
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demonstrating that only the target on increasing HIV/AIDS funding for low- and middle-
income countries (LMICs) had been achieved, while there were significant gaps in progress
towards the prevention and epidemiological targets (Table 3).
Thanks in large part to pressure from activists to expand access to antiretroviral therapy
(ART), quantitative targets for ART coverage began with WHO’s commitment to enrol 3 mil-
lion people on treatment by 2005. Later, the Joint United Nations Programme on HIV/AIDS’s
(UNAIDS’s) 15 by (20)15 initiative aimed to scale up and sustain ART coverage for 15 million
people, a target reached ahead of schedule in March 2015; this was heralded as fulfilment of
the MDG to ‘halt and reverse’ the epidemic [79].
UNAIDS’ 2011–2015 strategy set ambitious targets beneath a broader vision statement
of the Three Zeros—zero new HIV infections, zero AIDS-related deaths, and zero discrimina-
tion—which continues to frame the AIDS response [80]. The year 2014 saw the development
of the Fast Track strategy [81], setting out 10 targets, one of which was the ‘90-90-90’ target for
2020, which remains a significant marker of progress for countries. The 90-90-90 target aims
for 90% of persons living with HIV/AIDS (PLHIV) to be diagnosed, 90% of diagnosed people
to be on ART, and 90% of people on ART to have a fully suppressed viral load. Globally,
UNAIDS estimates that 75% of PLHIV knew their HIV status at the end of 2017. Their esti-
mates also suggest that 79% of diagnosed PLHIV were accessing treatment, and 81% of PLHIV
in treatment were virally suppressed [82]. The Fast-Track strategy has a particular focus on the
30 countries with the highest number of new infections, with each country defining its own
approach and 2020 milestones alongside the global targets.
The relative granularity of this approach contrasts with the more high-level 2015 SDG on
HIV (3.3): ‘By 2030, end the epidemics of AIDS. . .’, with the target indicator (3.3.1): ‘Number
of new HIV infections per 1,000 uninfected population, by sex, age and key populations’
[83,84]. Like the MDG target, the epidemiological measure defining the epidemic’s end is not
explicitly stated.
Targets set in the UNAIDS 2016–2021 strategy [85] and the 2016 Political Declaration on
Ending AIDS [86] demonstrate the difficulty of evaluating progress against complex targets
Fig 4. Major goals and targets for HIV/AIDS. ART, antiretroviral therapy; GFATM, Global Fund to Fight AIDS, Tuberculosis and
Malaria; LMIC, low- or middle-income country; MDG, Millennium Development Goal; PEPFAR, US President’s Emergency Plan
for AIDS Relief; UNAIDS, Joint United Nations Programme on HIV/AIDS.
https://doi.org/10.1371/journal.pmed.1002735.g004
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when high-quality data are not available. For example the target in the 2016 Declaration,
‘Ensure that at least 30% of all service delivery is community-led by 2020’ (Fast Track Commit-
ment 7 [87]) is challenging to monitor. The 2017 report on the 2016 Declaration by the UN
Secretary General [88] captures examples of good practice in community-led service delivery
but does not include quantitative data on global progress towards this target.
Several targets today are sensitive to the significant variation in the burden of HIV among
different subpopulations, recognising inequalities in vulnerability to HIV. For example, the
2016 Political Declaration includes a commitment to reduce the number of new HIV infec-
tions among adolescent girls and young women to below 100,000 per year (Commitment 5).
This demonstrates that targets are seeking to respond to structural drivers of the epidemic,
even if the available data suggest progress is too slow to address these; for example, in 2016,
Table 3. Targets set in the UNGASS 2001 declaration of commitment on HIV/AIDS.
Global target set in 2001 Declaration Indicator (cited in 2006 report) Global result reported in 2006
Reduce by 2005 HIV prevalence among
young men and women aged 15 to 24 in
the most affected countries by 25%
(Paragraph 47)
Percentage of young men and
women aged 15–24 who are
infected with HIV
Inconclusive (at the global level).
2006 report gives global prevalence
measures for this age cohort:
‘Women: 4.1%
(Measure of uncertainty: 3.2%–
5.1%)
Men: 1.6%
(Measure of uncertainty: 1.2%–
2.0%)’ but states,
‘No comparable global data on this
age cohort is available from
2001. Progress towards target can
only be measured in individual
countries.’
Ninety percent have access to
information, education, and services to
reduce their vulnerability to HIV
infection (Paragraph 53)
Percentage of youth aged 15–24
who correctly identify ways of
preventing HIV transmission
(Males) 33%
(Country range: 7%–50%
coverage)
(Females) 20%
(Country range: 8%–44%
coverage)
By 2005, reduce the proportion of infants
infected with HIV by 20% (Paragraph 54)
Estimated percentage of infants
born to mothers infected with
HIV who are infected in 2005
26% (in countries with generalised
epidemics).
‘There has been an estimated 10%
reduction in HIV transmission
between 2001 and 2005.’
Eighty percent of pregnant women
accessing antenatal care have
information, counselling, and other HIV
prevention services available to them,
increasing the availability of and
providing access for women and babies
infected with HIV to effective treatment
to reduce mother-to-child transmission of
HIV (Paragraph 54)
Percentage of HIV-positive
pregnant women receiving ARV
prophylaxis
9%
(Country range: 1%–59%
coverage)
Annual expenditure on the epidemic of
between US$7 billion and US$10 billion
in LMICs and countries experiencing, or
at risk of experiencing, rapid expansion of
HIV/AIDS (Paragraph 80)
Total annual expenditure US$8,297,000,000
Estimated range: $US7.4 billion–
US$8.5 billion
Abbreviations: ARV, antiretroviral; LMIC, low- or middle-income country; UNGASS, UN General Assembly Special
Session.
https://doi.org/10.1371/journal.pmed.1002735.t003
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there were 360,000 new HIV infections among adolescent girls and young women, only a 17%
decline since 2010 [89].
As discussed above, many process targets relating to funding provision, ART coverage, and
elimination of vertical HIV transmission have been achieved in several countries. However,
there has been more limited progress towards impact targets, for example, around the reduc-
tion of incidence or expanding access to combination prevention among key populations. This
highlights the inherent ambition of ‘Ending AIDS as a public threat’, given current rates of
progress towards the constituent targets. Paradoxically, there is a risk that insufficiently
nuanced rhetoric implying the end is in sight may deprioritise HIV, even while data illustrate
that renewed financing and political will are critical to achieving progress towards an aspira-
tional ‘end of AIDS’.
Discussion
Several important lessons emerge from our analysis that should be considered in developing
future goals and targets for HIV control.
Engagement of stakeholders as well as multidisciplinary scientific expertise
Scientific advancement and an enabling environment to implement effective interventions are
fundamental to the realisation of global targets for disease control. Alongside these factors, a
strong political, social, and economic commitment is necessary at all levels of society to achieve
success. Expertise from biomedical sciences, social sciences and economics, national pro-
gramme delivery, patient/carer representatives, and civil society more broadly is necessary
when setting new targets for disease control. National TB elimination programmes, for exam-
ple, have only had sustained success in industrialised countries that saw rapid socioeconomic
development and also addressed wider determinants of health. At the global level, the equitable
engagement of political stakeholders is also crucial. For malaria, only three sub-Saharan Afri-
can countries were present as full members at the WHA when the GMEP was adopted [34].
Global control strategies should, therefore, consult fully on target setting with national stake-
holders from high-burden settings.
Balance between ambition and caution when setting targets
A balance needs to be struck between ambitious, galvanising targets that drive funding, and
ones that reflect the complexities and local epidemiological variations in disease. The 1991 lep-
rosy elimination target was criticised for being arbitrary and ignoring the impact of secondary
disabilities. However, subsequent targets have not driven new funding in the same way that
this single target did. Global targets have been criticised for overlooking subpopulations of
high incidence and promoting oversimplified, generalisable solutions to complex problems
that are nuanced. On the other hand, numerous targets have been set for HIV and TB, many
of which have not been met in high-burden populations but which have helped sustain fund-
ing commitments. There is a tension between time-limited elimination targets that can keep
donor interest and the desire for community approaches that invest in social capital over a lon-
ger time but have the potential to be more equitable and better serve hard-to-reach groups
[90]. While the language of eradication and elimination can prove seductive to donors, the risk
exists of misdirecting efforts. Eradication requires significant up-front investment, which can
cause its supporters to oversell its feasibility. With leprosy, achieving the global elimination tar-
get undoubtedly resulted in a decline in investment in research, even though pockets of high
incidence and prevalence remain. For malaria, there is a risk of focusing elimination on areas
of low incidence and prevalence to shrink the global malaria map, at the cost of control in
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high-incidence areas. There are therefore clear ethical considerations and consequences to be
explored when setting ambitious goals and targets—particularly around their local effects and
the opportunity costs of foregoing other areas of public health.
Avoiding burdensome reporting and conflicting targets
In recent decades, the expansion of donor-driven disease programmes has led to a constant
stream of so-called SMART (Specific, Measurable, Achievable, Relevant, Time-bound) targets
and logframes (logical frameworks) to monitor projects and estimate impact [91]. There is a
clear utility in employing these methods to develop intermediate and adaptable targets that
allow for course corrections to programmes, and these can help address inequalities by includ-
ing harder-to-reach subpopulations. However, a balance needs to be struck to avoid overly
burdensome reporting requirements and the potential confusion of overlapping and some-
times conflicting targets both within and across vertical disease programmes. Linked to this is
a clear need to consciously distinguish between process and outcome targets. As seen with
HIV control, the achievement of process targets does not necessarily translate to a decrease in
new infections or mortality.
Retention of specialist skills
The experience with malaria and TB control in the 1970s and 1980s demonstrated a need to
ensure retention of expert skills and specialist services while moving towards integrated health
systems. The success of TB and HIV programmes are often intimately linked, with TB elimina-
tion in many settings dependent on adequate prevention and treatment of HIV [92]. Disease
control programmes should therefore look for opportunities to jointly develop targets and
integrate services and strategies where appropriate. The End TB strategy, for example, already
predicates future achievement of its 2050 TB target on universal health coverage (UHC), social
protection, and a range of SDG-related milestones, although relevant progress indicators have
not been framed around these [71,93].
Sustaining investment and political commitment as incidence falls
Finally, sustaining any elimination or eradication strategy in the end phase, as the cost per
case averted increases, will require prolonged investment and continuing political buy-in.
At present, 1.8 million people continue to be infected with HIV each year [17], and achiev-
ing elimination will only be possible with sufficient investment in research to develop vac-
cines, point-of-care diagnostics, and treatments; infrastructure upgrades that address wider
determinants of health; and health and surveillance systems that allow for equitable delivery
and access to services. For diseases like HIV that disproportionately affect marginalised
groups, equity-based service delivery targets become even more important as the elimina-
tion strategy nears its end. Human rights-based approaches that explicitly seek to tackle
stigma related to HIV and give key populations a stronger voice to influence policy will be
vital to ensure that equitable progress is made to control disease across all sectors of affected
populations [94].
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